Its hard not to focus on the $$$, but the only reason there is the potential for big money is because of human suffering.  I know we're focused primarily on CVD, targetting Diabetics with BETonMACE with a sub-population of CKD patients....and its hard to argue with that from a financial perspective, they likely represent two of the most lucrative indications.

But consider someone suffering from FSHD, a rare form of Muscular Dystrophy that we've learned Apabetalone may be able to treat.  Imagine that you suffered from this condition....or to add some emtional impact, imagine it was your child.  This condition causes a weakening and atropying of muscles...typically starting around eyes and mouth, and later spreading to other muscle groups.

It typically starts before the age of 20....again, imagine your child suffered from this insidious disease.  I imagine you would have a keen eye out for any developments, and scientific research being done that could benefit your child. And then you hear about Apabetalone.....and you're hopeful.  

Here's a tweet I saw that was tweeted November 14th.  

I hope Don isn't being so insistent on getting full value for Apabetelone that its severely retarding progress on a drug that, if successful, could have an enormous and positive impact on people's lives, especially kids.